

Atty's Docket: 10,203
 USS 09/424,686
 Hagen et al.,

In the last office action, Examiner maintained the restriction requirement and made it final. Thus limiting the claims to variant described in unamended claim element 14(e). Note, that this variant is now described in amended claim 14(a) and set forth in SEQ ID NO: 9.

Subsequent to receiving the office action, the undersigned sought the counsel of Cecilia Tsang of the PTO, who is a biotechnology specialist with respect to unity of invention issues. It is the understanding of the undersigned that after some discussion between the Examiner and Ms. Tsang, both agreed that it would be proper to examine groups V to VIII together. These groups refer to those delineated by the Examiner in the restriction requirement of December 30, 2002.

Appellants gratefully acknowledge the efforts of Examiner and Ms. Tsang in agreeing that groups V-VIII be examined.

In response, claim 14 has been amended to delete sequences that were allegedly anticipated by US '809 to Cech et al. Thus, the instant amendment overcomes the prior art.

The table below summarizes the current status of the claim elements in of original and unamended claim 14 (a) to (h).

EFFECT OF THE INSTANT AMENDMENT ON THE SEQUENCES RECITED IN ORIGINAL CLAIMS	
ORIGINAL CLAIM ELEMENT	AMENDED CLAIM ELEMENT
14(a) SEQ ID NO: 12	14(a) SEQ ID NO: 9
14(b) SEQ ID NO: 10	14(b) SEQ ID NO: 10
14(c) SEQ ID NO: 12	14(c) SEQ ID NO: 12
14(d) SEQ ID NO: 11	14(d) SEQ ID NO: 11
14(e) SEQ ID NO: 9	14(e) SEQ ID NO: 9
14(f) SEQ ID NO: 10	14(f) SEQ ID NO: 10
14(g) SEQ ID NO: 12	14(g) SEQ ID NO: 12
14(h) SEQ ID NO: 11	14(h) SEQ ID NO: 11

Atty's Docket:10,203
USS 09/424,686
Hagen et al.,

In addition to the prior art rejections, the Examiner issued rejections under §112, 1st paragraph due to the allegedly inadequate specification. For the most part, these rejections derived from errors in the previously submitted sequence listing.


In response, an amended sequence listing and Response to the Notice to Comply, was mailed on June 6, 2003. Appellants believe, in good faith, that the submission of June 6, 2003, provides the correct sequences and overcomes the written description rejections. Said amended sequence listing did not introduce new matter, because all of the sequences had been originally filed.

It is believed that the claims are in condition for examination on the merits, and are in fact, in condition for allowance.

The undersigned again gratefully acknowledges the efforts of Examiner and Ms. Tsang in agreeing to examine the claims as amended.

Respectfully Submitted,

Norris, McLaughlin & Marcus
220 East 42nd Street
New York, NY 10017
Telephone (212) 808-0700
Facsimile... (212) 808-0844


Theodore Gottlieb, PhD
Reg. Nr. 42,597

Atty's Docket:10,203
USS 09/424,686
Hagen et al.,

MARK UP OF AMENDED CLAIMS

14. (Amended) An isolated and purified nucleic acid sequence selected from the group consisting of:

- a) ~~a nucleic acid sequence encoding the protein of SEQ ID NO.: 2;~~
- b) ~~a nucleic acid sequence encoding the amino acid sequence of the catalytic telomerase subunit of Euplotis p123 which is functionally equivalent to the protein of SEQ ID NO.: 2;~~
- c) a nucleic acid sequence encoding the amino acid sequence of the catalytic telomerase subunit of yeasts which is functionally equivalent to the protein of SEQ ID NO.: 2;
- d) a first variant nucleic acid sequence of SEQ ID NO.: 1, wherein nucleotides 2345 to 2526 of SEQ ID NO.: 1 have been deleted;
- a e) a second variant nucleic acid sequence of SEQ ID NO.: 1, as described by SEQ ID NO: 9, wherein nucleotides 2184 to 2219 of SEQ ID NO.: 1 have been deleted;
- b f) a third variant nucleic acid sequence of SEQ ID NO.: 1, as described by SEQ ID NO: 10, wherein nucleotides 2184 to 2219 and 2345 to 2526 of SEQ ID NO.: 1 have been deleted;
- c g) a fourth variant nucleic acid sequence of SEQ ID NO.: 1, as described by SEQ ID NO: 12, wherein nucleotides 3219 to 3842 of SEQ ID NO.: 1 have been replaced by another sequence so that nucleotides 1783 to 3872 have the sequence of SEQ ID NO.: 7; and
- dh) a fragment variant of SEQ ID NO.: 1 as described by SEQ ID NO: 11, consisting of nucleotides 60 to 3470 of SEQ ID NO.: 1.

Atty's Docket:10,203
USS 09/424,686
Hagen et al.,

e) a nucleotide sequence that is at least 85% identical to the sequence described in a), b), c) or d), or a sequence complementary thereof, and wherein said variant encodes for active polypeptide having telomerase activity.

f) a sequence variant of the sequence described in a), b), c) or d) that results from the degeneracy of the genetic code, or a sequence complementary to said sequence variant, wherein the sequence variant encodes a polypeptide having telomerase activity.

15 (Amended) An isolated and purified nucleic acid sequence according to claim 14, which is a nucleic acid sequence encoding the encodes a protein having the catalytic activity of the protein of SEQ ID NO.: 2.

20. (Amended) An isolated and purified nucleic acid sequence according to claim 14, which is a second variant nucleic acid sequence of SEQ ID NO.: 1, said variant having the sequence described in SEQ ID NO: 9, wherein nucleotides 2184 to 2219 of SEQ ID NO.: 1 have been deleted.

21. (Amended) An isolated and purified nucleic acid sequence according to claim 14, which is a third variant nucleic acid sequence of SEQ ID NO.: 1, said variant having the sequence described in SEQ ID NO: 10, wherein nucleotides 2184 to 2219 and 2345 to 2526 of SEQ ID NO.: 1 have been deleted.

22. (Amended) An isolated and purified nucleic acid sequence according to claim 14, which is a fourth variant nucleic acid sequence of SEQ ID NO.: 1, wherein nucleotides 3219

Atty's Docket:10,203
USS 09/424,686
Hagen et al.,

to 3842 of SEQ ID NO.: 1 have been replaced, so that said variant has the sequence
described in SEQ ID NO: 12, by another sequence so that nucleotides 1783 to 3872 have
the sequence of SEQ ID NO.: 7.